Condition
Advanced Solid Tumor (Phase 1) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Advanced Solid Tumor (Phase 1) clinical trials that are recruiting, at sites in 7 countries (most in China (2), Belgium (1), Czechia (1)). By phase: Phase 1 (5). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 7Countries
Newest Advanced Solid Tumor (Phase 1) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Test of HSK46256, a PARP1 inhibitor, in adults with advanced solid tumors | Phase 1 | Shanghai | Recruiting | Jul 10, 2026 |
| AN8025 first-in-human dose exploration in advanced solid tumors | Phase 1 | Nedlands, Western Australia | Recruiting | Jun 10, 2026 |
| JLM019 Injection in Adults with Advanced Cancers | Phase 1 | Beijing, Beijing Municipality | Recruiting | Jun 3, 2026 |
| EP102 to target METTL3 in advanced solid tumors | Phase 1 | Brussels and 10 other locations | Recruiting | Sep 9, 2025 |
| APX-343A alone or with pembrolizumab for advanced solid tumors | Phase 1 | Seongnam and 2 other locations | Recruiting | Aug 14, 2025 |
All recruiting trials (5)
-
Test of HSK46256, a PARP1 inhibitor, in adults with advanced solid tumors
This early-phase study tests whether the drug HSK46256 is safe and tolerable and how it behaves in the body for adults with advanced solid tumors who have exhausted standard therapies.
-
AN8025 first-in-human dose exploration in advanced solid tumors
Researchers are testing different starting doses of AN8025 in adults with advanced solid tumors to see which dose is safe and tolerable and to find the highest dose that can be given safely.
-
JLM019 Injection in Adults with Advanced Cancers
This study tests JLM019 Injection in adults with advanced solid tumors or relapsed/refractory lymphomas to see if it’s safe and tolerable.
-
EP102 to target METTL3 in advanced solid tumors
This will test EP102, a drug that targets METTL3, in adults with advanced solid tumors who have no standard treatment options or whose cancer progressed after prior therapies.
-
APX-343A alone or with pembrolizumab for advanced solid tumors
This Phase 1 trial will test whether APX-343A by itself or combined with the immunotherapy pembrolizumab is safe and shows early benefit in adults with advanced solid tumors.
Related topics
Quick answers
How many Advanced Solid Tumor (Phase 1) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 7 countries. The most sites are in China (2 trials), Belgium (1 trial), Czechia (1 trial), Netherlands (1 trial), Spain (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.